The most commonly detected cancer-driver mutations were tumor protein p53 (TP53) mutations (74%; n = 148), followed by mutations in titin (TTN; 32%, n = 64), FAT atypical cadherin 1 (FAT1; 23%; n = 47), cyclin-dependent kinase inhibitor 2A (CDKN2A; 21%; n = 42), notch receptor 1 (NOTCH1; 17%; n = 34), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA; 17%; n = 34), mucin 16 (MUC16; 15%; n = 30), spectrin repeat-containing nuclear envelope protein 1 (SYNE1; 15%; n = 30), and caspase 8 (CASP8; 14%; n = 28; Fig 2A). This evidence concerns the gene CDKN2A and cancer.